ARTICLE | Finance
Beyond diabetes: T1D Fund’s new remit broadens venture base
How the JDRF T1D Fund is leveraging new insights around autoimmune biology to expand its scope
October 11, 2019 9:23 PM UTC
Updated on Oct 11, 2019 at 11:18 PM UTC
The JDRF T1D Fund’s investment in ImmunoMolecular Therapeutics this week is the latest example of how the venture philanthropy fund is leveraging new insights around autoimmune biology and the fund’s growing capital base to expand the scope of the fund.
Not only is the fund looking to attract VCs and companies outside of Type I diabetes to invest in the indication, it is now helping diabetes companies broaden their research remit to attract new sources of venture money...